Международная разработка
ClinicalTrials.gov
Исследования, вмешательства, заболевания, спонсоры, страны и результаты.
Фокус анализа
салметерол, флутиказон
1430
записей в выборке
Варианты написания учтены салметерол → salmeterol · флутиказон → fluticasone Подробнее Скрыть
- салметерол → salmeterol проверенная транслитерация · 100% Основание: версионированный словарь · словарь 1.1.0 Поиск: salmeterol, салметерол, сальметерол, салметерола ксинафоат, salmeterol xinafoate, sal meterol
- флутиказон → fluticasone проверенная транслитерация · 100% Основание: версионированный словарь · словарь 1.1.0 Поиск: fluticasone, флутиказон, flutikazon, флютиказон, флутиказона пропионат, fluticasone propionate
Для поиска доступны 597 478 исследований AACT · ClinicalTrials.gov. Показано совпадений: 177.
Результаты
ClinicalTrials.gov
факт источника
аналитический сигнал
Фильтры реестра По столбцам текущей таблицы Не заданы
| Исследование | Вмешательство / заболевание | Спонсор / страны | Фаза и статус | Сроки / участники | Результаты |
|---|---|---|---|---|---|
| Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma ↗ NCT00079937 AACT · ClinicalTrials.gov |
fluticasone
omalizumab
Asthma
|
Novartis Pharmaceuticals United States | PHASE3 Завершено | 30.04.2004 — 31.03.2008 628 участников | Опубликованы Первоисточник ↗ |
| Study Of Asthma In Patients Of African Descent NCT00102765 AACT · ClinicalTrials.gov |
fluticasone
fluticasone propionate powder
salmeterol powder
Asthma
|
GlaxoSmithKline United States | PHASE4 Завершено | 30.11.2004 — 30.04.2007 479 участников | Не найдены Первоисточник ↗ |
| Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate NCT00102882 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Kenya, Peru, Puerto Rico, United States | PHASE4 Завершено | 31.10.2004 — 31.01.2007 547 участников | Не найдены Первоисточник ↗ |
| Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911) NCT00127166 AACT · ClinicalTrials.gov |
fluticasone
montelukast sodium
salmeterol
Exercise Induced Asthma
|
Organon and Co Страны не указаны | PHASE3 Завершено | 31.12.2005 — 30.11.2008 154 участников | Опубликованы Первоисточник ↗ |
| The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial NCT00156819 AACT · ClinicalTrials.gov |
fluticasone
montelukast
fluticasone plus salmeterol
Asthma
|
JHSPH Center for Clinical Trials United States | PHASE4 Завершено | 30.06.2003 — 31.08.2006 500 участников | Опубликованы Первоисточник ↗ |
| Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications NCT00158834 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
fluticasone propionate combination product
Asthma
|
GlaxoSmithKline Netherlands | PHASE3 Завершено | 30.11.1999 — — 200 участников | Не найдены Первоисточник ↗ |
| Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies. NCT00169546 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline New Zealand, United Kingdom | PHASE4 Завершено | 31.01.2003 — 31.12.2005 64 участников | Не найдены Первоисточник ↗ |
| Treatment Of Symptomatic Asthma In Children NCT00197106 AACT · ClinicalTrials.gov |
salmeterol
100 mcg
fluticasone propionate 2 x 100 mcg
fluticasone propionate diskus inhaler 50
+1
Asthma
|
GlaxoSmithKline Netherlands | PHASE4 Завершено | 30.06.2005 — 31.10.2008 176 участников | Опубликованы Первоисточник ↗ |
| Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE) NCT00200967 AACT · ClinicalTrials.gov |
salmeterol
beclomethasone hfa
Asthma
|
Milton S. Hershey Medical Center United States | PHASE3 Завершено | 31.12.2004 — 29.02.2008 87 участников | Опубликованы Первоисточник ↗ |
| The Effect of Salmeterol on Eosinophil (EOS) Function NCT00214019 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Allergic Asthma
|
University of Wisconsin, Madison United States | Фаза не указана Завершено | 30.11.2003 — 31.01.2008 36 участников | Опубликованы Первоисточник ↗ |
| Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID NCT00235053 AACT · ClinicalTrials.gov |
fluticasone
50
salmeterol diskus 250
Asthma, Candidiasis, Oral, Voice Disorders
|
Allergy & Asthma Medical Group & Research Center United States | PHASE4 Завершено | 31.08.2005 — 30.11.2005 13 участников | Не найдены Первоисточник ↗ |
| Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg NCT00242775 AACT · ClinicalTrials.gov |
budesonide
salmeterol
fluticasone diskus
formoterol turbuhaler
+1
Asthma
|
AstraZeneca Argentina, Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Malaysia, Mexico, Philippines, Singapore, South Africa, Spain, Thailand, Vietnam | PHASE3 Завершено | 31.05.2005 — 31.05.2006 2 100 участников | Не найдены Первоисточник ↗ |
| DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults NCT00252863 AACT · ClinicalTrials.gov |
budesonide
fluticasone
4 5 g
50 g
as needed prn
budesonide turbuhaler 200 g
fluticasone discus 250 g
formoterol turbuhaler 160
formoterol turbuhaler 4 5 g
salbutamol pressurized metered dose inhaler pmdi 100 g
salmeterol discus 250
salmeterol discus 50 g
salmeterol discus 500
singulair 10 mg
symbicort
terbutaline turbuhaler 0 5 mg
theophylline 200 mg
theophylline 300 mg
used twice daily b i d
+16
Asthma
|
AstraZeneca Germany | PHASE3 Завершено | 31.12.2004 — 31.05.2006 1 600 участников | Не найдены Первоисточник ↗ |
| Study In Asthma Control NCT00273026 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Canada | PHASE4 Прекращено | 08.11.2004 — 28.03.2006 680 участников | Не найдены Первоисточник ↗ |
| Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product NCT00291382 AACT · ClinicalTrials.gov |
salmeterol
fluticasone propionate combination
Asthma
|
GlaxoSmithKline Belgium, Estonia, Finland, France, Germany, Italy, Latvia, Netherlands, Spain, Sweden | PHASE4 Завершено | 30.11.2005 — 31.07.2007 150 участников | Не найдены Первоисточник ↗ |
| Study Of Allergic Rhinitis In Patients Who Also Have Asthma NCT00296491 AACT · ClinicalTrials.gov |
fluticasone
advair diskus
fluticasone propionate fp
montelukast mon
salmeterol fsc
+2
Asthma
|
GlaxoSmithKline Canada, Estonia, Poland, United States | PHASE4 Завершено | 30.09.2005 — 31.10.2007 725 участников | Опубликованы Первоисточник ↗ |
| Study Of Patients With Allergic Rhinitis And Asthma NCT00296530 AACT · ClinicalTrials.gov |
fluticasone
montelukast
salmeterol
Asthma
|
GlaxoSmithKline United States | PHASE4 Завершено | 30.09.2005 — 31.07.2007 600 участников | Не найдены Первоисточник ↗ |
| Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101) ↗ NCT00306163 AACT · ClinicalTrials.gov |
fluticasone
ciclesonide
Asthma
|
AstraZeneca Netherlands | PHASE3 Завершено | 31.05.2006 — 30.09.2008 37 участников | Опубликованы Первоисточник ↗ |
| Viapaed Study In Children And Adolescents With Asthma NCT00315744 AACT · ClinicalTrials.gov |
fluticasone
salbutamol
salmeterol
Asthma
|
GlaxoSmithKline Germany | PHASE4 Завершено | 04.11.2004 — 12.04.2007 285 участников | Не найдены Первоисточник ↗ |
| Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA) ↗ NCT00318708 AACT · ClinicalTrials.gov |
fluticasone
clarithromycin
Asthma
|
Milton S. Hershey Medical Center United States | PHASE3 Завершено | 30.06.2006 — 30.04.2009 92 участников | Опубликованы Первоисточник ↗ |
| Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets NCT00328718 AACT · ClinicalTrials.gov |
salmeterol
100mcg bid
fluticasone propionate inhalation powder 50
montelukast 5mg qd
+1
Asthma
|
GlaxoSmithKline Argentina, Colombia, Costa Rica, Mexico, Peru, Turkey (Türkiye), Venezuela | PHASE3 Завершено | 31.10.2005 — 30.04.2007 526 участников | Не найдены Первоисточник ↗ |
| Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg NCT00350207 AACT · ClinicalTrials.gov |
salmeterol
tiotropium bromide
Asthma
|
Boehringer Ingelheim Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Russia, Slovakia, South Africa, Spain, Turkey (Türkiye), United Kingdom | PHASE2 Завершено | 31.07.2006 — — 388 участников | Опубликованы Первоисточник ↗ |
| A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control NCT00351143 AACT · ClinicalTrials.gov |
salmeterol
250 g
3 training sessions of compliance enhancement training
fluticasone propionate 50
+1
Asthma
|
GlaxoSmithKline Denmark, Switzerland | PHASE4 Завершено | 26.07.2005 — 13.06.2007 274 участников | Не найдены Первоисточник ↗ |
| Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids NCT00353873 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Belgium, Denmark, France, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Russia, Spain, Sweden | PHASE4 Завершено | 18.11.2005 — 26.10.2006 506 участников | Опубликованы Первоисточник ↗ |
| Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data NCT00363480 AACT · ClinicalTrials.gov |
salmeterol
250 mcg
fluticasone 50
salbutamol 100 mcg
+1
Asthma
|
GlaxoSmithKline Germany | PHASE4 Завершено | 17.05.2006 — 14.09.2007 221 участников | Опубликованы Первоисточник ↗ |
| Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics NCT00364442 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Germany | PHASE1 Завершено | 28.01.2005 — 13.04.2005 12 участников | Не найдены Первоисточник ↗ |
| Spacer Comparison In Adult Asthmatics NCT00369993 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline New Zealand | PHASE2 Завершено | 31.03.2005 — 31.05.2005 20 участников | Не найдены Первоисточник ↗ |
| Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies. NCT00370591 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline United Kingdom | PHASE4 Завершено | 31.12.2002 — 30.04.2004 48 участников | Не найдены Первоисточник ↗ |
| Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139) NCT00379288 AACT · ClinicalTrials.gov |
fluticasone
10 mcg bid
50 mcg bid
mometasone furoate combination mdi 200
mometasone furoate combination mdi 400
salmeterol 250
salmeterol 500
+4
Asthma
|
Organon and Co Страны не указаны | PHASE3 Завершено | 30.06.2006 — 30.11.2007 404 участников | Опубликованы Первоисточник ↗ |
| New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma ↗ NCT00393952 AACT · ClinicalTrials.gov |
fluticasone
10
fluticasone propionate 250
formoterol fumarate 10
formoterol fumarate 100
formoterol fumarate 250
+3
Asthma
|
SkyePharma AG Puerto Rico, United States | PHASE3 Завершено | 30.06.2006 — 30.04.2008 557 участников | Не найдены Первоисточник ↗ |
| Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma ↗ NCT00393991 AACT · ClinicalTrials.gov |
fluticasone
10
fluticasone propionate 100
formoterol fumarate 10
formoterol fumarate 100
+2
Asthma
|
SkyePharma AG Canada, United States | PHASE3 Завершено | 31.07.2006 — 30.04.2008 475 участников | Не найдены Первоисточник ↗ |
| New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma ↗ NCT00394121 AACT · ClinicalTrials.gov |
fluticasone
formoterol fumarate
Asthma
|
SkyePharma AG Germany, Hungary, Poland, Romania, United Kingdom | PHASE3 Завершено | 31.03.2006 — 31.07.2007 400 участников | Не найдены Первоисточник ↗ |
| Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma ↗ NCT00394199 AACT · ClinicalTrials.gov |
fluticasone
10
fluticasone propionate 100
formoterol fumarate 10
formoterol fumarate 100
+2
Asthma
|
SkyePharma AG Canada, United States | PHASE3 Завершено | 30.06.2006 — 29.02.2008 357 участников | Не найдены Первоисточник ↗ |
| Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER) NCT00395304 AACT · ClinicalTrials.gov |
fluticasone
montelukast
salmeterol
Asthma
|
Milton S. Hershey Medical Center United States | PHASE3 Завершено | 31.03.2007 — 31.12.2011 182 участников | Опубликованы Первоисточник ↗ |
| Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate ↗ NCT00400855 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
GlaxoSmithKline New Zealand | PHASE2 Завершено | 31.01.2005 — 31.08.2005 49 участников | Не найдены Первоисточник ↗ |
| Dose Ranging Study for Indacaterol in Japanese Asthma Patients NCT00403754 AACT · ClinicalTrials.gov |
indacaterol
salmeterol
Asthma
|
Novartis Pharmaceuticals Japan | PHASE2 Завершено | 30.11.2006 — 30.11.2007 41 участников | Опубликованы Первоисточник ↗ |
| Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD). NCT00404261 AACT · ClinicalTrials.gov |
fluticasone
salmeterol hfa
Asthma
|
GlaxoSmithKline Australia | PHASE4 Завершено | 31.01.2007 — 31.08.2007 132 участников | Не найдены Первоисточник ↗ |
| Inhaled Fluticasone Propionate: Effect on Parameters of Bone Metabolism in Patients With Mild to Moderate Asthma ↗ NCT00409630 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
University of Kansas Страны не указаны | Фаза не указана Отозвано | — — — 0 участников | Не найдены Первоисточник ↗ |
| Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) NCT00424008 AACT · ClinicalTrials.gov |
fluticasone
mometasone furoate
f mdi
formoterol mf
salmeterol f
sc dpi
+3
Asthma
|
Organon and Co Страны не указаны | PHASE3 Завершено | 30.04.2007 — 30.11.2008 722 участников | Опубликованы Первоисточник ↗ |
| A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma NCT00441441 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Australia, Canada, Chile, Costa Rica, Germany, Latvia, Lithuania, Mexico, Peru, Poland, Russia, Spain, United States | PHASE3 Завершено | 28.02.2007 — 31.01.2008 351 участников | Опубликованы Первоисточник ↗ |
| Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma NCT00448435 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
gw815sf hfa mdi
Bronchial Asthma
|
GlaxoSmithKline Japan | PHASE3 Завершено | 30.04.2007 — 31.01.2008 51 участников | Опубликованы Первоисточник ↗ |
| A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma NCT00452348 AACT · ClinicalTrials.gov |
fluticasone
50 mcg bid
fluticasone propionate 250 mcg bid
salmeterol xinofoate 250
+1
Asthma
|
GlaxoSmithKline Argentina, Brazil, Canada, Philippines, United States | PHASE4 Завершено | 31.05.2007 — 30.04.2009 628 участников | Опубликованы Первоисточник ↗ |
| A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma NCT00452699 AACT · ClinicalTrials.gov |
fluticasone
50 mcg bid
fluticasone propionate 250 mcg bid
salmeterol xinofoate 250
+1
Asthma
|
GlaxoSmithKline Argentina, Brazil, Canada, Philippines, United States | PHASE4 Завершено | 31.05.2007 — 31.05.2009 621 участников | Опубликованы Первоисточник ↗ |
| SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults NCT00461500 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
fluticasone propionate combination
Asthma
|
GlaxoSmithKline Страны не указаны | PHASE4 Завершено | 31.03.2007 — 31.12.2007 81 участников | Опубликованы Первоисточник ↗ |
| A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients. NCT00468975 AACT · ClinicalTrials.gov |
investigational:pf 610
salmeterol
355
Asthma
|
Pfizer Germany, Sweden, United Kingdom | PHASE2 Завершено | 31.05.2007 — — 42 участников | Не найдены Первоисточник ↗ |
| Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS) NCT00471809 AACT · ClinicalTrials.gov |
azithromycin
budesonide
montelukast
salmeterol
+1
Asthma
|
National Heart, Lung, and Blood Institute (NHLBI) United States | PHASE4 Прекращено | 31.03.2006 — 31.03.2007 210 участников | Не найдены Первоисточник ↗ |
| Study of FLUTIFORM® VS Seretide® in Paediatric Subjects With Asthma ↗ NCT00475813 AACT · ClinicalTrials.gov |
fluticasone
flutiform formoterol fumarate
Asthma
|
Mundipharma Research Limited Czechia, France, Germany, Hungary, Poland, Romania | PHASE3 Завершено | 31.03.2007 — 29.02.2008 211 участников | Не найдены Первоисточник ↗ |
| Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma ↗ NCT00476073 AACT · ClinicalTrials.gov |
fluticasone
flutiform formoterol fumarate
Asthma Bronchiale
|
Mundipharma Research Limited United Kingdom | PHASE3 Завершено | 30.04.2007 — 31.01.2008 228 участников | Не найдены Первоисточник ↗ |
| CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca. NCT00479739 AACT · ClinicalTrials.gov |
budesonide
salmeterol
fluticasone propionate or formoterol
Asthma
|
GlaxoSmithKline Australia, Austria, Belgium, Bulgaria, Canada, Estonia, Finland, Germany, Ireland, Latvia, Netherlands, New Zealand, North Macedonia, Spain, United Kingdom | PHASE4 Завершено | 30.11.2002 — 31.07.2004 700 участников | Не найдены Первоисточник ↗ |
| Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS) NCT00480649 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline South Korea | PHASE4 Завершено | 31.01.2004 — 30.09.2005 424 участников | Не найдены Первоисточник ↗ |
| Study Of RV-39 In Patients Who Also Have Asthma NCT00503009 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline United States | PHASE4 Прекращено | 31.10.2007 — 31.07.2008 16 участников | Опубликованы Первоисточник ↗ |
| Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma ↗ NCT00504062 AACT · ClinicalTrials.gov |
fluticasone
budesonide
Asthma
|
AstraZeneca Japan | PHASE3 Завершено | 31.10.2006 — 31.10.2007 240 участников | Не найдены Первоисточник ↗ |
| Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids? ↗ NCT00509197 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
Université de Montréal Canada | Фаза не указана Прекращено | 31.10.2007 — 30.09.2010 12 участников | Опубликованы Первоисточник ↗ |
| A Study of Montelukast (MK-0476) Compared With Fluticasone in Pediatric Participants With Chronic Asthma (MK-0476-303) ↗ NCT00540839 AACT · ClinicalTrials.gov |
fluticasone
montelukast sodium
Asthma, Bronchial
|
Organon and Co Страны не указаны | PHASE3 Отозвано | 30.11.2007 — — 0 участников | Не найдены Первоисточник ↗ |
| Leukotriene Receptor Antagonists or Steroids in Pre-School Asthma ↗ NCT00543686 AACT · ClinicalTrials.gov |
fluticasone
montelukast
Asthma
|
Johann Wolfgang Goethe University Hospital Germany | PHASE2 Завершено | 31.08.2007 — 28.02.2009 100 участников | Не найдены Первоисточник ↗ |
| Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma NCT00556673 AACT · ClinicalTrials.gov |
indacaterol maleate
mometasone furoate
salmeterol
fluticasone proprionate
+1
Asthma
|
Novartis France, Germany | PHASE2 Завершено | 31.10.2007 — 30.04.2008 31 участников | Опубликованы Первоисточник ↗ |
| Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications NCT00557180 AACT · ClinicalTrials.gov |
salmeterol
tiotropium bromide
beclomethasone dipropionate hfa
Asthma, Obesity
|
National Jewish Health United States | Фаза не указана Завершено | 31.10.2007 — 28.02.2011 33 участников | Не найдены Первоисточник ↗ |
| Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma ↗ NCT00557440 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
indacaterol maleate
mometasone
mometasone furoate
+2
Asthma
|
Novartis Belgium, Germany | PHASE2 Завершено | 30.11.2007 — 30.04.2008 37 участников | Опубликованы Первоисточник ↗ |
| Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) ↗ NCT00565266 AACT · ClinicalTrials.gov |
salmeterol
beclomethasone dipropionate
tiotropium bromide
Asthma
|
Milton S. Hershey Medical Center United States | PHASE3 Завершено | 31.05.2008 — 31.05.2010 210 участников | Опубликованы Первоисточник ↗ |
| Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma ↗ NCT00576069 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
formoterol
mometasone
prednisone
+3
Asthma
|
Gelb, Arthur F., M.D. United States | Фаза не указана Набор участников | 25.10.2007 — 30.06.2027 60 участников | Не найдены Первоисточник ↗ |
| How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment ↗ NCT00595361 AACT · ClinicalTrials.gov |
salmeterol
Asthma
|
Brigham and Women's Hospital United States | Фаза не указана Завершено | 31.01.2008 — 31.03.2012 30 участников | Опубликованы Первоисточник ↗ |
| Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma ↗ NCT00606242 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
University of California, San Francisco United States | PHASE4 Завершено | 31.01.2000 — 31.12.2007 44 участников | Не найдены Первоисточник ↗ |
| Induced Sputum Study (0000-065) ↗ NCT00623714 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
Merck Sharp & Dohme LLC Страны не указаны | PHASE1 Завершено | 31.01.2008 — 31.03.2009 13 участников | Опубликованы Первоисточник ↗ |
| Symbicort Onset of Action 2 ↗ NCT00646009 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
albuterol
budesonide
formoterol
+2
Asthma
|
AstraZeneca Страны не указаны | PHASE3 Завершено | 31.03.2003 — 31.08.2003 48 участников | Не найдены Первоисточник ↗ |
| Atlantis Symbicort ↗ NCT00646594 AACT · ClinicalTrials.gov |
fluticasone
budesonide
formoterol symbicort
salmeterol advair
+1
Asthma
|
AstraZeneca Страны не указаны | PHASE3 Завершено | 30.11.2003 — 31.01.2005 1 200 участников | Не найдены Первоисточник ↗ |
| Symbicort Onset of Action 1 ↗ NCT00646620 AACT · ClinicalTrials.gov |
fluticasone
albuterol ventolin
budesonide
formoterol symbicort
salmeterol advair diskus
+2
Asthma
|
AstraZeneca Страны не указаны | PHASE3 Завершено | 30.04.2003 — 30.09.2003 48 участников | Не найдены Первоисточник ↗ |
| Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics ↗ NCT00655616 AACT · ClinicalTrials.gov |
salmeterol
montelukast
Asthma
|
University of Dundee United Kingdom | Фаза не указана Завершено | 31.08.2007 — 31.12.2009 64 участников | Не найдены Первоисточник ↗ |
| Repeated High-dose Inhaled Corticosteroids for Asthma ↗ NCT00695604 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
University of Chicago United States | PHASE2 Отозвано | 31.05.2008 — 30.09.2011 0 участников | Не найдены Первоисточник ↗ |
| MethaCholine Bronchoprovocation Study (MeCIS) ↗ NCT00705341 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
Johns Hopkins Bloomberg School of Public Health United States | PHASE4 Завершено | 31.01.2009 — 28.02.2010 219 участников | Опубликованы Первоисточник ↗ |
| The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations ↗ NCT00706446 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
formoterol
tiotropium bromide
+2
Asthma
|
Brigham and Women's Hospital United States | Фаза не указана Прекращено | 30.06.2008 — 30.09.2011 255 участников | Опубликованы Первоисточник ↗ |
| The Effects of Montelukast on Smokers With Asthma ↗ NCT00712335 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
montelukast
Asthmatic Smokers, Non-asthmatic Smokers
|
Inje University South Korea | PHASE4 Завершено | 28.02.2007 — 31.05.2011 105 участников | Опубликованы Первоисточник ↗ |
| Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma ↗ NCT00734292 AACT · ClinicalTrials.gov |
fluticasone
formoterol fumarate
Mild to Moderate Asthma
|
SkyePharma AG United States | PHASE2 Завершено | 30.09.2008 — 31.10.2008 39 участников | Не найдены Первоисточник ↗ |
| Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma ↗ NCT00736801 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Allergic Asthma
|
University of Rostock Germany | Фаза не указана Завершено | 30.09.2005 — 30.04.2007 35 участников | Не найдены Первоисточник ↗ |
| Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients ↗ NCT00814216 AACT · ClinicalTrials.gov |
fluticasone
qav680
Asthma
|
Novartis Germany, India | PHASE2 Завершено | 31.12.2008 — — 37 участников | Не найдены Первоисточник ↗ |
| Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma ↗ NCT00829257 AACT · ClinicalTrials.gov |
fluticasone
hfa bdp
seretide
Asthma
|
University of Dundee United Kingdom | PHASE4 Завершено | 31.01.2009 — 31.07.2010 15 участников | Не найдены Первоисточник ↗ |
| Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients ↗ NCT00830102 AACT · ClinicalTrials.gov |
fluticasone
formoterol fumarate
Asthma
|
SkyePharma AG Ireland, United Kingdom | PHASE2 Завершено | 31.10.2004 — 31.01.2005 64 участников | Не найдены Первоисточник ↗ |
| Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma ↗ NCT00830505 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
University of Dundee United Kingdom | PHASE4 Завершено | 30.04.2009 — 31.05.2010 38 участников | Не найдены Первоисточник ↗ |
| Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma ↗ NCT00843193 AACT · ClinicalTrials.gov |
fluticasone
intravenous gsk679586
Asthma
|
GlaxoSmithKline France, Germany, Netherlands, Norway, Poland, South Africa, United Kingdom, United States | PHASE2 Завершено | 09.12.2008 — 25.07.2010 198 участников | Опубликованы Первоисточник ↗ |
| A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects ↗ NCT00877539 AACT · ClinicalTrials.gov |
fluticasone
pf 03526299
Asthma
|
Pfizer United Kingdom | PHASE1 Завершено | 30.06.2009 — 31.07.2010 29 участников | Не найдены Первоисточник ↗ |
| Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair ↗ NCT00927758 AACT · ClinicalTrials.gov |
fluticasone
250mcg
50 mcg
500mcg
50mcg
sal 100mcg
salmeterol flu
+4
Asthma
|
Sandoz United States | PHASE2 Завершено | 30.06.2009 — 31.12.2009 105 участников | Опубликованы Первоисточник ↗ |
| Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarkers of Asthma ↗ NCT00980707 AACT · ClinicalTrials.gov |
fluticasone
Allergic Asthma
|
Associated Scientists to Help Minimize Allergies United States | PHASE4 Завершено | 31.08.2009 — 30.11.2010 10 участников | Не найдены Первоисточник ↗ |
| Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma ↗ NCT00995657 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
University of Dundee United Kingdom | PHASE4 Завершено | 31.10.2009 — 31.12.2011 21 участников | Не найдены Первоисточник ↗ |
| Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma ↗ NCT00995800 AACT · ClinicalTrials.gov |
fluticasone
formoterol fumarate
Asthma
|
Mundipharma Research Limited Germany | PHASE2 Завершено | 31.10.2009 — 31.07.2010 46 участников | Не найдены Первоисточник ↗ |
| Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study ↗ NCT01018186 AACT · ClinicalTrials.gov |
fluticasone
fluticasone furoate
gw642444
Asthma
|
GlaxoSmithKline Germany, Thailand, Ukraine, United States | PHASE3 Завершено | 19.10.2009 — 12.05.2011 503 участников | Опубликованы Первоисточник ↗ |
| Efficacy and Safety of Different Doses of Indacaterol ↗ NCT01079130 AACT · ClinicalTrials.gov |
salmeterol
indacaterol
Asthma
|
Novartis Pharmaceuticals United States | PHASE3 Завершено | 28.02.2010 — — 511 участников | Опубликованы Первоисточник ↗ |
| BI 671800 ED in Steroid-naive Asthmatic Patients ↗ NCT01092143 AACT · ClinicalTrials.gov |
fluticasone
bi 671800
Asthma
|
Boehringer Ingelheim Australia, Canada, Colombia, Mexico, New Zealand, Peru, Philippines, South Korea, Taiwan, United States | PHASE2 Завершено | 18.03.2010 — 26.03.2011 389 участников | Опубликованы Первоисточник ↗ |
| Sub-Sensitivity to Long-Acting Bronchodilators (LABA) ↗ NCT01117116 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
formoterol
+1
Asthma
|
National Jewish Health United States | Фаза не указана Завершено | 31.03.2010 — 30.09.2013 20 участников | Опубликованы Первоисточник ↗ |
| Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management ↗ NCT01141439 AACT · ClinicalTrials.gov |
fluticasone
beclomethasone dipropionate
chlorofluorocarbon beclomethasone dipropionate
extra fine hydrofluoroalkane beclomethasone dipropionate
+1
Asthma
|
Research in Real-Life Ltd United Kingdom | Фаза не указана Завершено | 31.01.2001 — 31.07.2010 815 377 участников | Не найдены Первоисточник ↗ |
| Real-world Effectiveness of Combination Therapy in Asthma ↗ NCT01141465 AACT · ClinicalTrials.gov |
fluticasone
bud
budesonide
for dry powder inhaler
formoterol dry powder inhaler
formoterol metered dose inhaler
salmeterol dry powder inhaler
salmeterol metred dose inhaler
+5
Asthma
|
Research in Real-Life Ltd United Kingdom | Фаза не указана Завершено | 31.01.2001 — 28.02.2010 815 377 участников | Не найдены Первоисточник ↗ |
| HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents ↗ NCT01147848 AACT · ClinicalTrials.gov |
fluticasone
fluticasone furoate
salmeterol inhalation powder
vilanterol inhalation powder
+1
Asthma
|
GlaxoSmithKline Argentina, Chile, Netherlands, Philippines, South Korea, United States | PHASE3 Завершено | 30.06.2010 — 31.07.2011 810 участников | Опубликованы Первоисточник ↗ |
| Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents ↗ NCT01159912 AACT · ClinicalTrials.gov |
fluticasone
fluticasone furoate
Asthma
|
GlaxoSmithKline Belgium, Germany, Poland, Romania, United States | PHASE3 Завершено | 30.06.2010 — 16.01.2012 350 участников | Опубликованы Первоисточник ↗ |
| Fall Epidemic Viral Pediatric Study ↗ NCT01192178 AACT · ClinicalTrials.gov |
fluticasone
50 mcg bid
advairtm diskustm 100
Asthma
|
GlaxoSmithKline United States | PHASE4 Завершено | 31.08.2010 — 31.12.2010 339 участников | Опубликованы Первоисточник ↗ |
| A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients ↗ NCT01202084 AACT · ClinicalTrials.gov |
fluticasone
foraseq
formoterol
Asthma
|
Eurofarma Laboratorios S.A. Brazil | PHASE3 Завершено | 31.01.2012 — 30.11.2012 222 участников | Не найдены Первоисточник ↗ |
| A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma ↗ NCT01202097 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
seretide
Asthma
|
Eurofarma Laboratorios S.A. Brazil | PHASE3 Завершено | 31.08.2011 — 31.05.2012 334 участников | Не найдены Первоисточник ↗ |
| Mechanism(s) of Airflow Limitation During Exacerbation of Asthma ↗ NCT01225913 AACT · ClinicalTrials.gov |
fluticasone
budesonide
formoterol or fluticasone
salmeterol in all asthmatics
+1
Asthma
|
Gelb, Arthur F., M.D. United States | PHASE4 Набор участников | 31.10.2007 — 30.06.2027 50 участников | Не найдены Первоисточник ↗ |
| Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway ↗ NCT01231230 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
University of Miami Страны не указаны | Фаза не указана Завершено | 31.05.2007 — 31.08.2010 14 участников | Опубликованы Первоисточник ↗ |
| Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management ↗ NCT01242098 AACT · ClinicalTrials.gov |
fluticasone
fixed dose combination beclometasone dipropionate
fixed dose combination salmeterol
formoterol
+1
Asthma
|
Research in Real-Life Ltd United Kingdom | Фаза не указана Завершено | 31.01.2008 — 31.12.2011 137 участников | Не найдены Первоисточник ↗ |
| Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study ↗ NCT01287351 AACT · ClinicalTrials.gov |
fluticasone
extra fine hydrofluoroalkane beclometasone dipropionate
Asthma
|
Research in Real-Life Ltd United Kingdom | Фаза не указана Завершено | 31.01.2004 — 31.10.2010 82 903 участников | Не найдены Первоисточник ↗ |
| Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) ↗ NCT01290874 AACT · ClinicalTrials.gov |
salmeterol
formoterol
tiotropium
Asthma
|
Brigham and Women's Hospital United States | PHASE3 Завершено | 30.03.2011 — 31.07.2013 1 070 участников | Опубликованы Первоисточник ↗ |
| Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma ↗ NCT01312961 AACT · ClinicalTrials.gov |
fluticasone
albuterol
dupilumab
fluticasone monotherapy
levalbuterol
salmeterol combination therapy
+3
Asthma
|
Sanofi United States | PHASE2 Завершено | 31.03.2011 — 31.10.2012 104 участников | Опубликованы Первоисточник ↗ |
| Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population ↗ NCT01328964 AACT · ClinicalTrials.gov |
fluticasone
budesonide
montelukast
Asthma
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 30.06.2009 — 31.05.2010 9 906 участников | Опубликованы Первоисточник ↗ |
| Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids ↗ NCT01332344 AACT · ClinicalTrials.gov |
fluticasone
inhaled corticosteroids
salmeterol combination
Asthma
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 30.06.2009 — 30.06.2010 5 180 участников | Не найдены Первоисточник ↗ |
| Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit ↗ NCT01332357 AACT · ClinicalTrials.gov |
fluticasone
salmeterol combination ed md
salmeterol combination op md
Asthma
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 30.06.2009 — 31.07.2010 6 139 участников | Опубликованы Первоисточник ↗ |
| Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric) ↗ NCT01332422 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 30.11.2009 — 30.11.2012 300 участников | Не найдены Первоисточник ↗ |
| Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy ↗ NCT01347060 AACT · ClinicalTrials.gov |
fluticasone
inhaled corticosteroids
salmeterol xinafoate combination
Asthma
|
GlaxoSmithKline Страны не указаны | Фаза не указана Завершено | 31.07.2009 — 30.04.2010 17 448 участников | Опубликованы Первоисточник ↗ |
| Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). ↗ NCT01396278 AACT · ClinicalTrials.gov |
fluticasone
bi 54903
Asthma
|
Boehringer Ingelheim United States | PHASE2 Прекращено | 01.07.2011 — 14.12.2011 9 участников | Опубликованы Первоисточник ↗ |
| Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy ↗ NCT01397162 AACT · ClinicalTrials.gov |
fluticasone
bi 54903
Asthma
|
Boehringer Ingelheim United States | PHASE2 Прекращено | 21.07.2011 — 23.12.2011 29 участников | Опубликованы Первоисточник ↗ |
| Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS) ↗ NCT01397201 AACT · ClinicalTrials.gov |
fluticasone
bi 54903
Asthma
|
Boehringer Ingelheim United States | PHASE2 Прекращено | 01.07.2011 — 23.12.2011 30 участников | Опубликованы Первоисточник ↗ |
| Long-acting Beta Agonist Step Down Study ↗ NCT01437995 AACT · ClinicalTrials.gov |
fluticasone
salmeterol diskus
Asthma
|
Johns Hopkins University United States | PHASE4 Завершено | 31.03.2012 — 31.10.2015 459 участников | Опубликованы Первоисточник ↗ |
| A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids ↗ NCT01479621 AACT · ClinicalTrials.gov |
fluticasone
albuterol
salbutamol
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. Bulgaria, Croatia, Hungary, Israel, Poland, Serbia, Spain, Ukraine, United States | PHASE2 Завершено | 31.01.2012 — 31.07.2013 909 участников | Опубликованы Первоисточник ↗ |
| 12-Week Study in Adult Subjects With Asthma ↗ NCT01516073 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
Dey United States | PHASE2 Завершено | 31.03.2012 — 30.11.2013 629 участников | Не найдены Первоисточник ↗ |
| Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth ↗ NCT01520688 AACT · ClinicalTrials.gov |
fluticasone
beclomethasone
budesonide
Asthma
|
West Penn Allegheny Health System United States | PHASE4 Завершено | 29.02.2012 — 29.02.2016 32 участников | Опубликованы Первоисточник ↗ |
| Management of Asthma in School-age Children on Therapy ↗ NCT01526161 AACT · ClinicalTrials.gov |
salmeterol
inhaled fluticasone propionate
montelukast
Asthma
|
Professor Warren Lenney Страны не указаны | PHASE4 Завершено | 30.04.2009 — 31.01.2011 229 участников | Не найдены Первоисточник ↗ |
| Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment ↗ NCT01537133 AACT · ClinicalTrials.gov |
fluticasone
Asthma, Atopy
|
Milton S. Hershey Medical Center United States | Фаза не указана Завершено | 31.10.2012 — 31.07.2014 84 участников | Опубликованы Первоисточник ↗ |
| A Dose-ranging Study of Fluticasone Furoate (FF) ↗ NCT01563029 AACT · ClinicalTrials.gov |
fluticasone
fluticasone furoate
Asthma
|
GlaxoSmithKline Bulgaria, Georgia, Germany, Japan, Latvia, Mexico, Peru, Philippines, Poland, Puerto Rico, Russia, South Africa, Sweden, Ukraine, United States | PHASE2 Завершено | 28.03.2012 — 24.09.2014 597 участников | Опубликованы Первоисточник ↗ |
| A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications ↗ NCT01576718 AACT · ClinicalTrials.gov |
fluticasone
albuterol
salbutamol
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. Australia, Bulgaria, Canada, Croatia, Germany, Greece, Hungary, Ireland, Israel, New Zealand, Poland, Romania, Russia, Serbia, South Africa, Spain, Ukraine, United Kingdom, United States | PHASE2 Завершено | 30.04.2012 — 31.10.2013 889 участников | Опубликованы Первоисточник ↗ |
| Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder ↗ NCT01738087 AACT · ClinicalTrials.gov |
fluticasone
6 mcg dpi
nexthaler 100
nexthaler 200
+1
Asthmatic
|
Chiesi Farmaceutici S.p.A. United Kingdom | PHASE2 Завершено | 30.11.2012 — 31.01.2013 30 участников | Не найдены Первоисточник ↗ |
| Effects of QVAR in Smokers With Asthma ↗ NCT01741285 AACT · ClinicalTrials.gov |
fluticasone
beclomethasone clenil
beclomethasone qvar
Asthma
|
University Medical Center Groningen Netherlands | PHASE4 Завершено | 30.04.2013 — 31.12.2015 40 участников | Не найдены Первоисточник ↗ |
| Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects ↗ NCT01772368 AACT · ClinicalTrials.gov |
fluticasone
advair diskus
albuterol
fs mdpi
+1
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. United States | PHASE2 Завершено | 31.01.2013 — 30.06.2013 72 участников | Опубликованы Первоисточник ↗ |
| Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients ↗ NCT01795664 AACT · ClinicalTrials.gov |
salmeterol
fluticasone propionate hfa pmdi
seretide evohaler
Asthma
|
FLUIDDA nv Belgium | PHASE3 Завершено | 31.03.2013 — 31.08.2013 16 участников | Не найдены Первоисточник ↗ |
| Qvar vs FP in Pediatrics ↗ NCT01877954 AACT · ClinicalTrials.gov |
fluticasone
extra fine hydrofluoroalkane beclometasone dipropionate
Asthma
|
Research in Real-Life Ltd Страны не указаны | Фаза не указана Завершено | 28.02.2011 — 31.03.2013 2 654 участников | Не найдены Первоисточник ↗ |
| Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma ↗ NCT01881412 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
Rhode Island Hospital United States | Фаза не указана Прекращено | 31.08.2012 — 30.04.2018 118 участников | Опубликованы Первоисточник ↗ |
| ROTAHALER Device Optimization Study ↗ NCT01890863 AACT · ClinicalTrials.gov |
fluticasone
salmeterol xinafoate diskus
salmeterol xinafoate rotacap
Asthma
|
GlaxoSmithKline Australia | PHASE1 Завершено | 05.08.2013 — 30.09.2013 36 участников | Не найдены Первоисточник ↗ |
| Effects of Particle Size in Small Airways Dysfunction ↗ NCT01892787 AACT · ClinicalTrials.gov |
salmeterol
formoterol
Asthma
|
University of Dundee United Kingdom | PHASE4 Завершено | 31.07.2013 — 31.12.2014 17 участников | Не найдены Первоисточник ↗ |
| Dose-Response of Salmeterol in Children ↗ NCT01907334 AACT · ClinicalTrials.gov |
fluticasone
50 g
advair diskus100
albuterol
methacholine chloride
+2
Asthma
|
University of Florida United States | PHASE4 Завершено | 31.08.2013 — 31.07.2014 10 участников | Опубликованы Первоисточник ↗ |
| Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial ↗ NCT02061280 AACT · ClinicalTrials.gov |
fluticasone
50 dry powder inhaler
fluticasone 100mcg dry powder inhaler
salmeterol 100
salmeterol 250
+2
Asthma
|
Nemours Children's Clinic United States | PHASE4 Завершено | 31.10.2013 — 17.02.2017 108 участников | Опубликованы Первоисточник ↗ |
| A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid ↗ NCT02094274 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
las40468
Asthma
|
Almirall, S.A. Germany, United Kingdom | PHASE1 Завершено | 30.11.2013 — 31.05.2014 30 участников | Не найдены Первоисточник ↗ |
| Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma ↗ NCT02139644 AACT · ClinicalTrials.gov |
fluticasone
albuterol
beclomethasone dipropionate
fs mdpi
salbutamol
+2
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. Canada, Czechia, Hungary, Poland, Russia, South Africa, Ukraine, United States | PHASE3 Завершено | 30.06.2014 — 30.09.2015 787 участников | Опубликованы Первоисточник ↗ |
| Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma ↗ NCT02141854 AACT · ClinicalTrials.gov |
fluticasone
albuterol
fs mdpi
salmeterol hfa mdi
+1
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. Canada, Czechia, Hungary, Poland, Russia, South Africa, Thailand, Ukraine, United States | PHASE3 Завершено | 30.06.2014 — 30.09.2015 882 участников | Опубликованы Первоисточник ↗ |
| Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus ↗ NCT02162485 AACT · ClinicalTrials.gov |
salmeterol
fluticasone easyhaler
fluticasone easyhaler with charcoal
seretide diskus
seretide diskus with charcoal
+2
Asthma
|
Orion Corporation, Orion Pharma Finland | PHASE1 Завершено | 30.06.2014 — 30.09.2015 129 участников | Не найдены Первоисточник ↗ |
| Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma ↗ NCT02175771 AACT · ClinicalTrials.gov |
fluticasone
advair diskus
albuterol
fs mdpi
salbutamol hfa
+2
Persistent Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. United States | PHASE3 Завершено | 31.07.2014 — 31.07.2015 758 участников | Опубликованы Первоисточник ↗ |
| A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler ↗ NCT02218762 AACT · ClinicalTrials.gov |
fluticasone
salmeterol xinafoate diskus
salmeterol xinafoate rotacaps
Asthma
|
GlaxoSmithKline Страны не указаны | PHASE1 Отозвано | 31.10.2014 — 30.06.2015 0 участников | Не найдены Первоисточник ↗ |
| MGR001 / Advair Diskus Local Equivalence Study in Asthma ↗ NCT02245672 AACT · ClinicalTrials.gov |
salmeterol
advair fixed dose combination of fluticasone propionate
mgr001 fixed dose combination of fluticasone propionate
Asthma
|
Mylan Pharma UK Ltd. United States | PHASE3 Завершено | 31.10.2014 — 31.07.2015 1 128 участников | Опубликованы Первоисточник ↗ |
| Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma ↗ NCT02260492 AACT · ClinicalTrials.gov |
salmeterol
advair diskus combination of fluticasone propionate
ot329 combination of fluticasone propionate
Asthma
|
Oriel Therapeutics United States | PHASE1 Завершено | 30.09.2014 — 31.07.2015 879 участников | Опубликованы Первоисточник ↗ |
| An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma ↗ NCT02301975 AACT · ClinicalTrials.gov |
fluticasone
25 mcg via ellipta inhaler
50 mcg via accuhaler
diskus inhaler
fluticasone furoate
fluticasone propionate 250 mcg via accuhaler
salmeterol 250
vilanterol 100
+5
Asthma
|
GlaxoSmithKline Argentina, Brazil, Chile, Czechia, Germany, Mexico, Netherlands, Romania, Russia, South Korea, Spain, United States | PHASE3 Завершено | 01.03.2015 — 25.11.2016 1 526 участников | Опубликованы Первоисточник ↗ |
| AMP-BPT and His-BPT for Assessment of Asthma ↗ NCT02318043 AACT · ClinicalTrials.gov |
fluticasone
4 5mcg
50mcg
fomorterol 160
inhaled corticosteroids usually budesonide
salmeterol 250
+3
Asthma
|
Guangzhou Institute of Respiratory Disease Страны не указаны | Фаза не указана Завершено | 31.01.2007 — 31.12.2007 84 участников | Не найдены Первоисточник ↗ |
| A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers ↗ NCT02403713 AACT · ClinicalTrials.gov |
fluticasone
formoterol
formoterol bai
formoterol pmdi with spacer
formoterol pmdi without spacer
formoterol pmdi without spacer low dose
+3
Asthma
|
Mundipharma Research Limited United Kingdom | PHASE1 Завершено | 31.08.2014 — 30.09.2015 125 участников | Не найдены Первоисточник ↗ |
| Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients ↗ NCT02415179 AACT · ClinicalTrials.gov |
salmeterol
formoterol
inhaled fluticasone
inhaled mometasone
+1
Asthma
|
Mahidol University Thailand | Фаза не указана Завершено | 31.05.2015 — 29.02.2016 52 участников | Не найдены Первоисточник ↗ |
| Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older ↗ NCT02437604 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. United States | PHASE1 Завершено | 31.05.2015 — 30.09.2015 43 участников | Не найдены Первоисточник ↗ |
| A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma ↗ NCT02446418 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
fluticasone furoate
formoterol fumarate
vilanterol
+3
Asthma
|
GlaxoSmithKline France, Germany | PHASE3 Завершено | 09.07.2015 — 20.07.2017 423 участников | Опубликованы Первоисточник ↗ |
| Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block ↗ NCT02466347 AACT · ClinicalTrials.gov |
fluticasone
salmeterol as xinafoate
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
|
Intech Biopharm Ltd. Taiwan | PHASE1 Завершено | 30.06.2014 — 31.08.2014 45 участников | Не найдены Первоисточник ↗ |
| Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block ↗ NCT02466503 AACT · ClinicalTrials.gov |
fluticasone
salmeterol as xinafoate
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
|
Intech Biopharm Ltd. Taiwan | PHASE1 Завершено | 31.08.2014 — 30.09.2014 45 участников | Не найдены Первоисточник ↗ |
| Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol ↗ NCT02491970 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
formoterol
Asthma
|
Mundipharma Korea Ltd Страны не указаны | PHASE4 Прекращено | 31.08.2015 — 31.05.2017 15 участников | Не найдены Первоисточник ↗ |
| A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma ↗ NCT02554786 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
indacaterol acetate
mometasone furoate
+1
Asthma
|
Novartis Pharmaceuticals Bulgaria, China, Croatia, Czechia, Egypt, Estonia, Germany, Guatemala, Hungary, India, Ireland, Japan, Latvia, Lithuania, Mexico, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, United Kingdom, United States | PHASE3 Завершено | 29.12.2015 — 28.06.2019 2 216 участников | Опубликованы Первоисточник ↗ |
| Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma ↗ NCT02571777 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
160
320
50
80
qmf149 150
qvm149 150
+5
Asthma
|
Novartis Pharmaceuticals Argentina, Austria, Belgium, Bulgaria, Canada, Chile, China, Colombia, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Jordan, Latvia, Lebanon, Lithuania, Mexico, Netherlands, Peru, Philippines, Poland, Portugal, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Thailand, United Kingdom, Vietnam | PHASE3 Завершено | 08.12.2015 — 14.06.2019 3 092 участников | Опубликованы Первоисточник ↗ |
| Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma ↗ NCT02573233 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
budesonide
dupilumab sar231893
formoterol
mometasone furoate
regn668
+4
Asthma
|
Sanofi Canada, Denmark, Germany, Sweden, United Kingdom, United States | PHASE2 Завершено | 27.01.2016 — 03.01.2018 42 участников | Опубликованы Первоисточник ↗ |
| Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma ↗ NCT02577497 AACT · ClinicalTrials.gov |
fluticasone
beclomethasone
Asthma
|
University of Virginia United States | PHASE4 Завершено | 30.06.2016 — 06.07.2018 31 участников | Не найдены Первоисточник ↗ |
| Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate ↗ NCT02649478 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
50
advair diskus 100
+1
Asthma
|
Roxane Laboratories United States | Фаза не указана Завершено | 31.08.2014 — 30.11.2015 1 430 участников | Не найдены Первоисточник ↗ |
| Changes in the Lung Clearance Index in Pediatric Patients With Asthma ↗ NCT02678949 AACT · ClinicalTrials.gov |
fluticasone
inhaled albuterol
Childhood Asthma
|
Hospital Infantil de Mexico Federico Gomez Mexico | Фаза не указана Статус не определён | 31.03.2016 — 31.12.2016 105 участников | Не найдены Первоисточник ↗ |
| A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma ↗ NCT02680561 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
fluticasone propionate mdpi
salmeterol mdpi
+1
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. United States | PHASE1 Завершено | 30.04.2016 — 31.08.2016 20 участников | Не найдены Первоисточник ↗ |
| A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma ↗ NCT02753712 AACT · ClinicalTrials.gov |
fluticasone
formoterol bai
vilanterol dpi relvar ellipta dpi
Asthma
|
Mundipharma Research Limited Australia, New Zealand, Slovakia, Sweden, United Kingdom | PHASE3 Завершено | 15.06.2016 — 14.08.2017 105 участников | Не найдены Первоисточник ↗ |
| A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma ↗ NCT02924688 AACT · ClinicalTrials.gov |
fluticasone
25 mcg
31 25
62 5
albuterol
ff
salbutamol
salmeterol fsc
umec
vi 100
vi 200
+8
Asthma
|
GlaxoSmithKline Argentina, Australia, Canada, Germany, Italy, Japan, Netherlands, Poland, Romania, Russia, South Africa, South Korea, Spain, United Kingdom, United States | PHASE3 Завершено | 13.10.2016 — 22.02.2019 2 436 участников | Опубликованы Первоисточник ↗ |
| Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler ↗ NCT02980133 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. Georgia, Hungary, Russia, Ukraine, United States | PHASE3 Завершено | 28.12.2016 — 13.04.2019 841 участников | Опубликованы Первоисточник ↗ |
| Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus ↗ NCT03060044 AACT · ClinicalTrials.gov |
salmeterol
fluticasone easyhaler
fluticasone easyhaler with charcoal
seretide diskus
seretide diskus with charcoal
+2
Asthma
|
Orion Corporation, Orion Pharma Finland | PHASE1 Завершено | 31.07.2016 — 30.11.2016 64 участников | Не найдены Первоисточник ↗ |
| Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. ↗ NCT03063086 AACT · ClinicalTrials.gov |
salmeterol
160 g o d
50
500 g b i d
80 g o d
fluticasone fdc 50
qvm149 150
+4
Asthma
|
Novartis Pharmaceuticals Bulgaria, China, Germany, Netherlands, Romania, United Kingdom | PHASE2 Завершено | 21.01.2017 — 02.08.2018 116 участников | Опубликованы Первоисточник ↗ |
| Study of REGN3500 and Dupilumab in Patients With Asthma ↗ NCT03112577 AACT · ClinicalTrials.gov |
fluticasone
dupilumab
regn3500
Asthma, Allergic
|
Regeneron Pharmaceuticals United Kingdom, United States | PHASE1 Завершено | 15.06.2017 — 09.12.2019 32 участников | Не найдены Первоисточник ↗ |
| Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium ↗ NCT03158311 AACT · ClinicalTrials.gov |
salmeterol
fluticasone plus tiotropium
qvm149
Asthma
|
Novartis Pharmaceuticals Argentina, Chile, Colombia, Czechia, Germany, Greece, Hungary, India, Israel, Mexico, Peru, Poland, Russia, Serbia, Slovakia, South Africa, Spain, Taiwan, Turkey (Türkiye), Vietnam | PHASE3 Завершено | 05.02.2018 — 19.07.2019 1 426 участников | Опубликованы Первоисточник ↗ |
| Efficacy of Intermittent Tiotropium in Early Childhood Wheezing ↗ NCT03199976 AACT · ClinicalTrials.gov |
fluticasone
salbutamol
tiotropium bromide
Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing, Obstruction Airway
|
Helsinki University Central Hospital Finland | PHASE4 Прекращено | 20.04.2016 — 18.11.2020 80 участников | Опубликованы Первоисточник ↗ |
| Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma ↗ NCT03207243 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
gsk3772847
Asthma
|
GlaxoSmithKline Australia, Canada, Mexico, Russia, Ukraine, United States | PHASE2 Завершено | 14.09.2017 — 15.05.2019 165 участников | Опубликованы Первоисточник ↗ |
| Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years ↗ NCT03273946 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
GlaxoSmithKline China | Фаза не указана Завершено | 09.01.2018 — 27.09.2018 158 участников | Опубликованы Первоисточник ↗ |
| Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years ↗ NCT03387241 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
formoterol
Asthma
|
Mundipharma (China) Pharmaceutical Co. Ltd China | PHASE3 Статус не определён | 02.06.2017 — 30.03.2020 330 участников | Не найдены Первоисточник ↗ |
| BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients ↗ NCT03394989 AACT · ClinicalTrials.gov |
fluticasone
50 dry powder inhaler
50 g
60 actuat
advair diskus 100
salmeterol 100
+3
Bronchial Asthma
|
Cipla Ltd. United States | PHASE3 Завершено | 17.10.2018 — 31.03.2020 1 366 участников | Не найдены Первоисточник ↗ |
| Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma ↗ NCT03461627 AACT · ClinicalTrials.gov |
salmeterol
fluticasone propinate powder
seretide
Asthma
|
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. China | PHASE3 Статус не определён | 01.04.2017 — 31.10.2018 300 участников | Не найдены Первоисточник ↗ |
| Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. ↗ NCT03468790 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
cmab007
symbicort
ventolin
+2
Asthma, Allergic
|
Shanghai Biomabs Pharmaceutical Co., Ltd. China | PHASE3 Завершено | 09.05.2018 — 09.03.2021 393 участников | Не найдены Первоисточник ↗ |
| Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg) ↗ NCT03535870 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
100 mcg 50 mcg inhalation powder
advair diskus
+1
Asthma
|
West-Ward Pharmaceutical United States | Фаза не указана Завершено | 26.04.2018 — 10.09.2019 1 556 участников | Не найдены Первоисточник ↗ |
| Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma ↗ NCT03756883 AACT · ClinicalTrials.gov |
fluticasone
salmeterol inhalation powder
Asthma
|
Actavis Inc. United States | PHASE3 Завершено | 03.12.2018 — 10.11.2019 999 участников | Опубликованы Первоисточник ↗ |
| Personalized Treatment Algorithms for Difficult-to-treat Asthma ↗ NCT04179461 AACT · ClinicalTrials.gov |
fluticasone
antihistamine
asthma controller medication
azithromycin
cholecalciferol
emollient cream
+3
Asthma in Children
|
Children's Hospital Medical Center, Cincinnati United States | PHASE2 Завершено | 16.03.2018 — 03.10.2019 21 участников | Опубликованы Первоисточник ↗ |
| Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients ↗ NCT04271839 AACT · ClinicalTrials.gov |
fluticasone
formoterol k haler medium strength
laba high strength
standard of care ics
+1
Persistent Asthma
|
Mundipharma Pharmaceuticals S.L. Страны не указаны | PHASE4 Отозвано | 11.06.2020 — 31.05.2021 0 участников | Не найдены Первоисточник ↗ |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) ↗ NCT04278404 AACT · ClinicalTrials.gov |
fluticasone
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
|
Duke University Canada, United States | Фаза не указана Набор участников | 05.03.2020 — 31.07.2027 5 000 участников | Не найдены Первоисточник ↗ |
| Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma ↗ NCT04503460 AACT · ClinicalTrials.gov |
salmeterol
salmeterol fluticasone
Asthma
|
Imperial College London United Kingdom | PHASE4 Статус не определён | 23.07.2021 — 30.09.2024 24 участников | Не найдены Первоисточник ↗ |
| A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma ↗ NCT04677959 AACT · ClinicalTrials.gov |
fluticasone
albuterol
salmeterol fs
standard of care asthma medication
standard of care rescue medication
+2
Asthma
|
Teva Branded Pharmaceutical Products R&D, Inc. United States | PHASE4 Завершено | 16.02.2021 — 10.03.2022 427 участников | Опубликованы Первоисточник ↗ |
| Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone ↗ NCT05457855 AACT · ClinicalTrials.gov |
fluticasone
montelukast
Asthma
|
Brigham and Women's Hospital United States | Фаза не указана Завершено | 01.02.2022 — 31.12.2023 51 533 участников | Опубликованы Первоисточник ↗ |
| A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. ↗ NCT05776927 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
qvm149
Asthma
|
Novartis Pharmaceuticals Страны не указаны | PHASE3 Набор ещё не начат | 31.07.2026 — 30.01.2029 188 участников | Не найдены Первоисточник ↗ |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma ↗ NCT06572228 AACT · ClinicalTrials.gov |
fluticasone
dupilumab
Asthma
|
Regeneron Pharmaceuticals Canada, Denmark, Germany, Poland, Puerto Rico, United States | PHASE4 Активно, набор завершён | 26.08.2024 — 24.04.2027 120 участников | Не найдены Первоисточник ↗ |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma ↗ NCT06664619 AACT · ClinicalTrials.gov |
fluticasone
abs
fp
Asthma
|
Teva Branded Pharmaceutical Products R&D LLC Argentina, Bulgaria, Czechia, Germany, Israel, Mexico, Poland, Romania, Serbia, Slovakia, South Africa, Turkey (Türkiye), United States | PHASE3 Набор участников | 12.12.2024 — 19.09.2026 724 участников | Не найдены Первоисточник ↗ |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma ↗ NCT06676319 AACT · ClinicalTrials.gov |
fluticasone
salmeterol
albuterol
budesonide
formoterol
lunsekimig
short acting beta agonists saba
+4
Asthma
|
Sanofi Argentina, Belgium, Brazil, Canada, Chile, China, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Poland, Romania, South Africa, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom, United States | PHASE2 Активно, набор завершён | 07.11.2024 — 19.07.2027 556 участников | Не найдены Первоисточник ↗ |
| Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate ↗ NCT07664527 AACT · ClinicalTrials.gov |
fluticasone
Asthma
|
University of Wisconsin, Madison United States | PHASE4 Набор ещё не начат | 31.08.2026 — 30.04.2027 20 участников | Не найдены Первоисточник ↗ |